EQT Corp

EQT

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$22.0M

1 fund

Feb 17, 2026

$1.0M

1 fund

-95% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 19,527Value: $1.0M

**Signal Note: EQT Corp Position Initiation** Driehaus Capital's new $1.0M position in EQT Corp appears misaligned with the fund's biotech focus, as EQT is a major natural gas producer with no meaningful pharmaceutical pipeline—this likely reflects a portfolio rebalancing or energy sector hedge rather than a biotech investment thesis. The position size and sector mismatch suggest this is not a core conviction bet and warrants monitoring for potential exit or clarification of Driehaus's strategic intent.

Eventide Asset ManagementNEW

More EQT Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AXON2 funds NVDA2 funds VEEV2 funds VCYT2 funds LBRT2 funds RMBS2 funds UNP2 funds LITE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide Asset Management initiates $22.0M position in EQT Corp** This represents a significant sector pivot rather than a biotech signal—EQT is a diversified energy infrastructure company (natural gas, water treatment), not a drug developer. The $22.0M position suggests Eventide's values-based mandate may be expanding into energy infrastructure, though this warrants clarification on whether the allocation reflects ESG-screened energy assets or signals a strategic reallocation away from pure-play biotech.